Synapse - Works

Results (2639)

Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: Phase 1b results of SYMPHONY-1

Meeting Abstract

Batlevi, C. L.; Salles, G.; Park, S. I.; Phillips, T. J.; Amengual, J. E.; Andorsky, D.; Campbell, P.; McKay, P.; Leonard, J. P.; Sondhi, M.; more...
Blood (2022)

Fulltext@MSK | Save

Observational cohort study of people living with HIV (PWH) treated with CD19-directed CAR T cell therapy for B-cell lymphoid malignancies - Interim results of AIDS Malignancy Consortium (AMC) study AMC-113

Meeting Abstract

Barta, S. K.; Noy, A.; Pasquini, M. C.; He, N.; Hunt, T.; Litovich, C.; Ibrahim, U.; Baiocchi, R. A.; Ambinder, R. F.
Blood (2022)

Fulltext@MSK | Save

Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders

Meeting Abstract

Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
Blood (2022)

Fulltext@MSK | Save

DNA methylation-based Burkitt Lymphoma epitypes have distinct molecular and clinical features

Meeting Abstract

Thomas, N.; Dreval, K.; Gerhard, D. S.; Hilton, L. K.; Abramson, J. S.; Bartlett, N. L.; Bethony, J.; Bowen, J.; Bryan, A.; Casper, C.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Meeting Abstract

Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
Blood (2022)

Fulltext@MSK | Save

Age, albumin, and LDH predict outcome of patients with limited stage peripheral T cell lymphoma: A prognostic model developed on 244 cases enrolled in the T cell project 1 by the International T Cell Project Network

Meeting Abstract

Hapgood, G.; Civallero, M.; Stepanishyna, Y.; Vose, J. M.; Cabrera, M. E.; Advani, R. H.; Pileri, S. A.; Manni, M.; Horwitz, S. M.; Foss, F. M.; more...
Blood (2022)

Fulltext@MSK | Save

CNS relapse in T-cell lymphoma index: A risk score to predict central nervous system relapse in patients with T-cell lymphomas

Meeting Abstract

Bhansali, R. S.; Ellin, F.; Cao, M.; Relander, T.; Li, W.; Long, Q.; Ganesan, N.; Stuver, R.; Horwitz, S. M.; Wudhikarn, K.; more...
Blood (2022)

Fulltext@MSK | Save

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study

Meeting Abstract

Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
Blood (2022)

Fulltext@MSK | Save

Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study

Meeting Abstract

Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Lenz, G.; Trneny, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; Sharman, J. P.; more...
Blood (2022)

Fulltext@MSK | Save

Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma

Meeting Abstract

Herrera, A. F.; Chen, L.; Crombie, J. L.; Cohen, J. B.; Advani, R. H.; LaCasce, A. S.; Popplewell, L. L.; Puverel, S.; Peters, L.; Daniels, S.; more...
Blood (2022)

Fulltext@MSK | Save